Abrams William J 4

What Happened

• William J. Abrams, Executive Vice President, Supply Chain Solutions at Medline (MDLN), was the recipient of multiple equity awards and incentive‑unit grants reported on a Form 4 covering transactions dated December 16, 2025 (and a small grant dated March 5, 2026). Reported acquisitions include outright share awards and several classes of derivative interests (Incentive Units/RSUs) with no cash purchase price disclosed (one grant on 2026-03-05 shows $0.00). Specific line items reported include share amounts such as 495,680; 30,655; and 17,854 (direct awards) and derivative amounts including 495,680; 30,655; 1,129,447; 170,204; 91,078; and 97,531 (all shown as acquisitions/awards).

Key Details

• Transaction dates and filing: primary transactions dated 2025-12-16; additional grant dated 2026-03-05. Form filed 2026-03-06 (appears late relative to the typical 2‑business‑day Form 4 deadline).
• Prices/consideration: most items show N/A for price (typical for equity reclassifications/awards); one grant on 2026-03-05 listed at $0.00 (no cash paid).
• Shares owned after transaction: not specified in the provided filing details.
• Notable footnotes and mechanics:
  • F1: Many securities were acquired in connection with a pre‑IPO reclassification of Medline Holdings, LP interests (described in the S-1); those interests were previously reported on the Reporting Person’s Form 3 (Dec 17, 2025).
  • F4: Some awards are RSUs with vesting (25% on June 15, 2026; remainder in three annual installments starting Mar 1, 2027).
  • F6/F7 & F5: Several items are Incentive Units (profit‑interest style awards) convertible into Common Units per a formula, and Common Units are exchangeable one‑for‑one for Class A common stock under an exchange agreement; Incentive Units are held indirectly through Medline Management Aggregator LLC.
  • F2: Class B common stock entries represent shares with one vote each but no economic value; they are cancelled if the holder exchanges Common Units for Class A stock.
  • Vesting notes: some incentive units show partial vesting (e.g., 20% or 40% vested now, remaining amounts vesting over 2026–2030 per footnotes F8–F11).
• Reporting timeliness: filing date indicates the Form 4 was filed months after the December 16, 2025 transactions; that late filing is factual but does not itself indicate the insider’s intent.

Context

• These entries reflect equity awards and reclassification tied to Medline’s transition to a public company structure (pre‑IPO reclassification and grants), and many are subject to vesting schedules or conversion mechanics rather than immediate free trading shares. Such awards are routine for senior executives and — absent a cash purchase — do not indicate a buy/sell market sentiment.